1. Cognitive Impairment Associated With Schizophrenia (CIAS)Pipeline Review, H2 2015 Published on : October - 2015 No. Pages : 110

2. About Cognitive Impairment Associated with Schizophrenia (CIAS)Pipeline Review, H2 2015 Research Beam added report on “Cognitive Impairment Associated with Schizophrenia (CIAS)Pipeline Review, H2 2015”. Summary Global Markets Directs, Cognitive Impairment Associated with Schizophrenia (CIAS)Pipeline Review, H2 2015, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated with Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated with Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Get Full Details On : http://www.researchbeam.com/cognitive-impairment-associated-with- schizophrenia-cias-pipeline-review-h2-2015-markethttp://www.researchbeam.com/cognitive-impairment-associated-with- schizophrenia-cias-pipeline-review-h2-2015-market Report Overview.

3. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Report Overview.

4. Scope The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects. Report Overview

5. Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter- strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics. etc. Report Overview

6. List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 10 Therapeutics Development 11 Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 11 Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis 12 Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 13 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Table Of Contents

7. Atrial Fibrillation - Products under Development by Companies 18 Atrial Fibrillation - Products under Investigation by Universities/Institutes 20 Atrial Fibrillation - Companies Involved in Therapeutics Development 21 ARCA biopharma, Inc. 21 Armetheon, Inc. 22 AstraZeneca Plc 23 Bristol-Myers Squibb Company 24 Cardiome Pharma Corp. 25 Daiichi Sankyo Company, Limited 26 Gilead Sciences, Inc. 27 Isis Pharmaceuticals, Inc. 28 Laboratoires Pierre Fabre SA 29 Nissan Chemical Industries, Ltd. 30 Nyken BV 31

8. Early Stage Products 17 Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 18 Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 20 AbbVie Inc. 20 Amarantus Bioscience Holdings, Inc. 21 Astellas Pharma Inc. 22 Avineuro Pharmaceuticals, Inc. 23 Bristol-Myers Squibb Company 24 Eli Lilly and Company 25 Enquiry about this report @ http://www.researchbeam.com/cognitive-impairment-associated- with-schizophrenia-cias-pipeline-review-h2-2015-market/enquire-about-reporthttp://www.researchbeam.com/cognitive-impairment-associated- with-schizophrenia-cias-pipeline-review-h2-2015-market/enquire-about-report Table Of Contents

9. FOR MORE DETAILS Visit us at : http://www.researchbeam.com/cognitive-impairment- associated-with-schizophrenia-cias-pipeline-review-h2-2015- market Stay With Us: 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States TELEPHONE: +1 (800) 910-6452 E-MAIL: sales@researchbeam.com